| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Department of Neurology,*
University of
Cambridge, United Kingdom; Medical Research Council Laboratory of
Molecular Biology,
Hills Road, Cambridge CB2
2QH, United Kingdom; Department of Pathology,
Vrije Universiteit, Amsterdam; and the Departments of
Clinical Genetics§
and
Neurology,¶
Erasmus University Rotterdam,
The Netherlands
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Paraffin-embedded sections of frontal, temporal, and parietal cortices, hippocampus, cerebellum, and different subcortical nuclei from 3 patients from HFTD1 (53, 66, and 76 years), and 3 patients from HFTD2 (54, 56, and 57 years) together with 2 AD patients (74 and 80 years) were used for immunohistochemistry. Fresh-frozen tissue from hippocampus, temporal cortex, and frontal cortex of the 3 patients from HFTD1, 2 AD patients (65 and 78 years) and 2 control subjects (68 and 72 years) was used for biochemical studies.
Immunohistochemistry
For immunohistochemistry sections were incubated with phosphorylation-dependent (AT8, AT180, AT270, and AT10017 (E. Vanmechelen, Innogenetics]; PHF1 [P. Davies], 12 E818 (P. Seubert, Athena Neurosciences), and phosphorylation-independent anti-tau antibodies (BR133, BR134, BR304, BR189).11 Polyclonal and monoclonal antibodies raised against amyloid Aß (Ab 2332; V.M.-Y Lee) and anti-heparan sulfate antibody 10E419 (Seikagaku, Japan) were also used. Immunohistochemistry was performed as previously reported.3
Tau Extraction, Dephosphorylation, and Immunoblotting
Sarkosyl-insoluble tau was extracted and dephosphorylated as previously described.4,20 PHF-tau samples were run on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto Immobilon P (Millipore), incubated overnight at 4°C with the primary antibodies and stained using the biotin-avidin Vectastain system (Vector Laboratories). Soluble tau was extracted using 2.5% perchloric acid as previously described.21
Electron Microscopy
Aliquots of sarkosyl-insoluble tau were processed as previously described for electron microscopy and for immunogold electron microscopy.22
| Results |
|---|
|
|
|---|
The three brains from HFTD2 also showed severe loss of neurons and gliosis of the frontal and temporal cortex, and in less extent of the parietal cortex. Neuronal loss was also present in the hippocampus and gyrus parahippocampalis as previously reported.16,23,24 Caudate nucleus was severely degenerated. Severe loss of pigmented cells occurred in the substantia nigra. A few Pick bodies were observed in one case.16
Immunohistochemistry
In both families phosphorylation-dependent and -independent
anti-tau antibodies stained numerous deposits in the superficial layer
23 and deep layer 6 of the frontal, temporal, and parietal cortices,
brain stem, gyrus cinguli, the granule cells of dentate gyrus (DG)
including its inner molecular layer, cornu ammonis (CA) 1 and 2,
entorhinal cortex, and substantia nigra in all cases examined (Figure 1)
. These deposits were mainly of the
pre-tangle type located in the perinuclear region and cell body and
sometimes extending to the apical dendrites of neurons.
|
In HFTD2 the granule cells in the DG showed various Pick-like
inclusions, often with associated cytoplasmic and perinuclear tau
staining (Figure 1, C and D)
. Neurons in pre-tangle stage were present
in CA4, whereas globose staining of neurons was often associated with
Pick-like bodies in CA1, CA2, and subiculum, with occasional
extracellular neurofibrillary tangles in CA2 in one case. Antibody 12E8
did not stain Pick-like bodies or perinuclear and cytoplasmic tau
deposits; in a few cells it stained deposits in one side of the
cytoplasm and in the DG some cells presented granular staining. The
number of glial cells stained by anti-tau antibodies was much lower in
HFTD2 compared to HFTD1. ß-Amyloid deposits were absent.
Electron Microscopy
Electron microscopy of dispersed filament preparations from
frontal and temporal cortices and hippocampal formation of three
patients from HFTD1 showed tau-containing filaments structurally
different from Alzheimer's disease PHFs. The majority of these
filaments were irregularly twisted ribbons of width about 15 nm and
crossover spacing greater than 130 nm (Figure 2, A and B)
. A minority consisted of
straight filaments about 12 nm wide with a strongly stranded rope-like
appearance (Figure 2, C and D)
.
|
Sarkosyl-insoluble tau extracted from frontal and temporal
cortices and hippocampal formation from 3 patients of HFTD1 appeared in
immunoblots as two major bands of 64 and 68 kd and a minor band of 72
kd (Figure 3A)
. After alkaline
phosphatase treatment of sarkosyl-insoluble material, tau appeared as
three major bands corresponding to the isoforms with 4 repeats and no
amino-terminal insert, and to the isoforms with 3 and 4 repeats and the
29 amino acid amino-terminal insert (Figure 3B)
. The pattern of soluble
tau in HFTD1 was similar to that in control brains (data not shown).
|
| Discussion |
|---|
|
|
|---|
In HFTD2, the first family described as familial Pick disease,16,23,24 Pick body-like inclusions were observed in the granular layer of the DG and cortex, often associated with perinuclear and cytoplasmic staining. The presence of strong cytoplasmic tau staining surrounding the Pick-like inclusions and the absence of information about the characteristics of the filaments in the inclusions have led us to name these inclusions Pick-like bodies instead of Pick bodies, until more ultrastructural and biochemical data become available. Such inclusions have not been described in other FTDP-17 families and this is the first time a mutation in the tau gene appears linked to Pick-like bodies. In both families antibody 12E8 stained mainly granular structures, sometimes surrounded by a vacuole, and a few neurons, similar to the pattern observed in MSTD.4 It did not stain the Pick body-like inclusions in HFTD2, suggesting that they are similar to those in Pick's disease.25,26
The two families have mutations in different microtubule-binding
repeats of tau, so the population of tau molecules is affected in
different ways. In HFTD1 the P301L mutation lies in exon 10, which is
included in 4 repeat isoforms but not in 3 repeat isoforms (Figure 3C)
.
In HFTD2 the G272V mutation lies in exon 9 and therefore affects all 6
isoforms (Figure 3C)
. In both cases it is likely that the binding to
microtubules of those tau isoforms carrying a mutation will be
affected, probably adversely. The balance between binding of 3 and 4
repeat isoforms will be changed in HFTD1, producing an effect similar
to that created by a splicing mutation in MSTD, which favors production
of 4 repeat isoforms5,15
and leads to ribbon-like
twisted filaments4
as here. However, in MSTD the
sarkosyl-insoluble material contains only 4 repeat isoforms, so perhaps
in HFTD1 the 3 repeat tau isoform, found after alkaline phosphatase
treatment, co-assembles in the filaments, or the mutated 4 repeat tau
isoform prevents normal 3 repeat tau isoform from binding to
microtubules by occupying binding places. The tau isoform with 3
repeats and 29-amino acid amino-terminal insert is abundant in human
brain and does not contain the P301L mutation, so its presence in
filaments shows that they contain both normal and mutated tau
molecules.
In HFTD2, for which no fresh tissue is available, all isoforms are affected, as in Seattle family A3,13 where filaments are of AD type,3,12 so filaments in HFTD2 may be of AD type but the presence of Pick body-like structures may also give straight filaments.27 Furthermore, it has been reported that Pick bodies contain only tau isoforms with 3 repeats,26 so it remains to be seen if this is the case in the Pick body-like inclusions. However, in both families disturbance of tau binding may destabilize microtubules and lead to accumulation of tau in an inappropriate compartment, hyperphosphorylation, and assembly of abnormal filaments, resulting in cell death.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported in part by the UK Medical Research Council (to RAC, MGS) and by The Royal Society of London (to MGS).
Accepted for publication August 6, 1998.
| References |
|---|
|
|
|---|
isoform distribution and phosphorylation. Ann Neurol 1998, 43:193-204[Medline]
This article has been cited by other articles:
![]() |
H. Aoyagi, M. Hasegawa, and A. Tamaoka Fibrillogenic Nuclei Composed of P301L Mutant Tau Induce Elongation of P301L Tau but Not Wild-type Tau J. Biol. Chem., July 13, 2007; 282(28): 20309 - 20318. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Rosenmann, N. Grigoriadis, D. Karussis, M. Boimel, O. Touloumi, H. Ovadia, and O. Abramsky Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein. Arch Neurol, October 1, 2006; 63(10): 1459 - 1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Murakami, E. Paitel, T. Kawarabayashi, M. Ikeda, M. A. Chishti, C. Janus, E. Matsubara, A. Sasaki, T. Kawarai, A. L. Phinney, et al. Cortical Neuronal and Glial Pathology in TgTauP301L Transgenic Mice: Neuronal Degeneration, Memory Disturbance, and Phenotypic Variation Am. J. Pathol., October 1, 2006; 169(4): 1365 - 1375. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schindowski, A. Bretteville, K. Leroy, S. Begard, J.-P. Brion, M. Hamdane, and L. Buee Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits Am. J. Pathol., August 1, 2006; 169(2): 599 - 616. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Bunker, K. Kamath, L. Wilson, M. A. Jordan, and S. C. Feinstein FTDP-17 Mutations Compromise the Ability of Tau to Regulate Microtubule Dynamics in Cells J. Biol. Chem., April 28, 2006; 281(17): 11856 - 11863. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Bronner, B. C. ter Meulen, A. Azmani, L. A. Severijnen, R. Willemsen, W. Kamphorst, R. Ravid, P. Heutink, and J. C. van Swieten Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology Brain, November 1, 2005; 128(11): 2645 - 2653. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Pickering-Brown, M. Baker, T. Nonaka, K. Ikeda, S. Sharma, J. Mackenzie, S. A. Simpson, J. W. Moore, J. S. Snowden, R. de Silva, et al. Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene Brain, June 1, 2004; 127(6): 1415 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Bunker, L. Wilson, M. A. Jordan, and S. C. Feinstein Modulation of Microtubule Dynamics by Tau in Living Cells: Implications for Development and Neurodegeneration Mol. Biol. Cell, June 1, 2004; 15(6): 2720 - 2728. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wen, S. Yang, R. Liu, A. M. Brun-Zinkernagel, P. Koulen, and J. W. Simpkins Transient Cerebral Ischemia Induces Aberrant Neuronal Cell Cycle Re-entry and Alzheimer's Disease-like Tauopathy in Female Rats J. Biol. Chem., May 21, 2004; 279(21): 22684 - 22692. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferrari, F. Hoerndli, T. Baechi, R. M. Nitsch, and J. Gotz {beta}-Amyloid Induces Paired Helical Filament-like Tau Filaments in Tissue Culture J. Biol. Chem., October 10, 2003; 278(41): 40162 - 40168. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Van Deerlin, L. H. Gill, J. M. Farmer, J. Q. Trojanowski, and V. M-Y. Lee Familial Frontotemporal Dementia: From Gene Discovery to Clinical Molecular Diagnostics Clin. Chem., October 1, 2003; 49(10): 1717 - 1725. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Rosso, E. van Herpen, Y. A. L. Pijnenburg, N. S. M. Schoonenboom, P. Scheltens, P. Heutink, and J. C. van Swieten Total tau and Phosphorylated tau 181 Levels in the Cerebrospinal Fluid of Patients With Frontotemporal Dementia Due to P301L and G272V tau Mutations Arch Neurol, September 1, 2003; 60(9): 1209 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jiang, H. Tang, N. Havlioglu, X. Zhang, S. Stamm, R. Yan, and J. Y. Wu Mutations in Tau Gene Exon 10 Associated with FTDP-17 Alter the Activity of an Exonic Splicing Enhancer to Interact with Tra2{beta} J. Biol. Chem., May 23, 2003; 278(21): 18997 - 19007. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Neugroschl and K. L. Davis Biological Markers in Alzheimer Disease Am J Geriatr Psychiatry, December 1, 2002; 10(6): 660 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Allen, E. Ingram, M. Takao, M. J. Smith, R. Jakes, K. Virdee, H. Yoshida, M. Holzer, M. Craxton, P. C. Emson, et al. Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein J. Neurosci., November 1, 2002; 22(21): 9340 - 9351. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Zhukareva, K. Shah, K. Uryu, H. Braak, K. Del Tredici, S. Sundarraj, C. Clark, J. Q. Trojanowski, and V. M.-Y. Lee Biochemical Analysis of {tau} Proteins in Argyrophilic Grain Disease, Alzheimer's Disease, and Pick's Disease : A Comparative Study Am. J. Pathol., October 1, 2002; 161(4): 1135 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Janssen, E. K. Warrington, H. R. Morris, P. Lantos, J. Brown, T. Revesz, N. Wood, M. N. Khan, L. Cipolotti, N. C. Fox, et al. Clinical features of frontotemporal dementia due to the intronic tau 10+16 mutation Neurology, April 23, 2002; 58(8): 1161 - 1168. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Rosso, W. Kamphorst, B. de Graaf, R. Willemsen, R. Ravid, M. F. Niermeijer, M. G. Spillantini, P. Heutink, and J. C. van Swieten Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22 Brain, October 1, 2001; 124(10): 1948 - 1957. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sergeant, B. Sablonniere, S. Schraen-Maschke, A. Ghestem, C.-A. Maurage, A. Wattez, P. Vermersch, and A. Delacourte Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1 Hum. Mol. Genet., September 1, 2001; 10(19): 2143 - 2155. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gotz, F. Chen, J. van Dorpe, and R. M. Nitsch Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Abeta 42 Fibrils Science, August 24, 2001; 293(5534): 1491 - 1495. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. K. Wszolek, Y. Tsuboi, R. J. Uitti, L. Reed, M. L. Hutton, D. W. Dickson, P. M. Stanford, G. M. Halliday, W. S. Brooks, J. B.J. Kwok, et al. Progressive supranuclear palsy as a disease phenotype caused by the S305S tau gene mutation Brain, August 1, 2001; 124(8): 1666 - 1670. [Full Text] [PDF] |
||||
![]() |
M. Hutton Missense and splice site mutations in tau associated with FTDP-17: Multiple pathogenic mechanisms Neurology, June 12, 2001; 56(90004): S21 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. King, N. Ghoshal, J. S. Wall, L. I. Binder, and H. Ksiezak-Reding Structural Analysis of Pick's Disease-Derived and in Vitro-Assembled Tau Filaments Am. J. Pathol., April 1, 2001; 158(4): 1481 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyasaka, M. Morishima-Kawashima, R. Ravid, P. Heutink, J. C. van Swieten, K. Nagashima, and Y. Ihara Molecular Analysis of Mutant and Wild-Type Tau Deposited in the Brain Affected by the FTDP-17 R406W Mutation Am. J. Pathol., February 1, 2001; 158(2): 373 - 379. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Rizzu, M. Joosse, R. Ravid, A. Hoogeveen, W. Kamphorst, J. C. van Swieten, R. Willemsen, and P. Heutink Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients Hum. Mol. Genet., December 1, 2000; 9(20): 3075 - 3082. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. von Bergen, P. Friedhoff, J. Biernat, J. Heberle, E.-M. Mandelkow, and E. Mandelkow Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming beta structure PNAS, May 9, 2000; 97(10): 5129 - 5134. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Arima, A. Kowalska, M. Hasegawa, M. Mukoyama, R. Watanabe, M. Kawai, K. Takahashi, T. Iwatsubo, T. Tabira, and N. Sunohara Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene Neurology, May 9, 2000; 54(9): 1787 - 1795. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Stanford, G. M. Halliday, W. S. Brooks, J. B. J. Kwok, C. E. Storey, H. Creasey, J. G. L. Morris, M. J. Fulham, and P. R. Schofield Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations Brain, May 1, 2000; 123(5): 880 - 893. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Heutink Untangling tau-related dementia Hum. Mol. Genet., April 1, 2000; 9(6): 979 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Wilhelmsen The tangled biology of tau PNAS, June 22, 1999; 96(13): 7120 - 7121. [Full Text] [PDF] |
||||
![]() |
N. Matsumura, T. Yamazaki, and Y. Ihara Stable Expression in Chinese Hamster Ovary Cells of Mutated Tau Genes Causing Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP-17) Am. J. Pathol., June 1, 1999; 154(6): 1649 - 1656. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Bird, D. Nochlin, P. Poorkaj, M. Cherrier, J. Kaye, H. Payami, E. Peskind, T. H. Lampe, E. Nemens, P. J. Boyer, et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L) Brain, April 1, 1999; 122(4): 741 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Goedert and M. Hasegawa The Tauopathies : Toward an Experimental Animal Model Am. J. Pathol., January 1, 1999; 154(1): 1 - 6. [Full Text] [PDF] |
||||
![]() |
J. Gotz, F. Chen, R. Barmettler, and R. M. Nitsch Tau Filament Formation in Transgenic Mice Expressing P301L Tau J. Biol. Chem., January 5, 2001; 276(1): 529 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. D'Souza and G. D. Schellenberg Determinants of 4-Repeat Tau Expression. COORDINATION BETWEEN ENHANCING AND INHIBITORY SPLICING SEQUENCES FOR EXON 10 INCLUSION J. Biol. Chem., June 2, 2000; 275(23): 17700 - 17709. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||